Cargando…

Effect of favipiravir and an anti-inflammatory strategy for COVID-19

Detalles Bibliográficos
Autores principales:	Yamamura, Hitoshi, Matsuura, Hiroshi, Nakagawa, Junichiro, Fukuoka, Hiroshi, Domi, Hisaya, Chujoh, Satoru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7347251/ https://www.ncbi.nlm.nih.gov/pubmed/32646499 http://dx.doi.org/10.1186/s13054-020-03137-5

Ejemplares similares

A continuous intravenous insulin infusion protocol to manage high-dose methylprednisolone-induced hyperglycemia in patients with severe COVID-19
por: Takahashi, Yoshihito, et al.
Publicado: (2022)

Simple prognostic factors and change of inflammatory markers in patients with severe coronavirus disease 2019: a single‐center observational study
por: Domi, Hisaya, et al.
Publicado: (2021)

Serial computed tomography findings of Coronavirus disease 2019 (COVID-19) pneumonia treated with favipiravir and steroid therapy: report of 11 cases
por: Irizato, Naoki, et al.
Publicado: (2021)

Cardiopulmonary arrest upon admission caused by pilsicainide hydrochloride intoxication: A case report
por: Takahashi, Yoshihito, et al.
Publicado: (2023)

Use of Favipiravir in Lactating Mother With COVID-19
por: Karabayır, Nalan, et al.
Publicado: (2021)

Hematological Malignancy Patients, COVID-19, and Favipiravir
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

Favipiravir and the Need for Early Ambulatory Treatment of COVID-19
por: Korman, Tony M.
Publicado: (2021)

Favipiravir Experience in Covid-19 Positive Myasthenia Gravis Patients
por: Yevgi, Recep, et al.
Publicado: (2021)

Clinical efficacy and safety of favipiravir in the treatment of COVID-19 patients
por: Chen, Ping-Jen, et al.
Publicado: (2021)

Adverse events associated with nafamostat mesylate and favipiravir treatment in COVID-19 patients
por: Hifumi, Toru, et al.
Publicado: (2020)

Population pharmacokinetics of favipiravir in patients with COVID‐19
por: Irie, Kei, et al.
Publicado: (2021)

ICU admission and favipiravir
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

Two cases of cryptogenic life‐threatening hemoptysis – identification and management of bleeding point
por: Okuda, Kazunori, et al.
Publicado: (2016)

Pharmacokinetics of Favipiravir in Critically Ill Patients With COVID‐19
por: Irie, Kei, et al.
Publicado: (2020)

An unusual case of bluish discoloration of the cornea after favipiravir therapy for COVID-19
por: Raiturcar, Tanvi P, et al.
Publicado: (2021)

Re: Efficacy of favipiravir in adults with mild COVID-19 by Bosaeed et al.
por: Mori, Nobuaki
Publicado: (2022)

Evaluation of the effect of favipiravir on patients with COVID-19
por: Kamali, Alireza, et al.
Publicado: (2023)

Role of favipiravir in the treatment of COVID-19
por: Joshi, Shashank, et al.
Publicado: (2021)

Intravenous Immunoglobulin and Favipiravir treatment for A Kidney Transplant Patient with Severe Covid-19 Pneumonia
por: Tatar, Erhan, et al.
Publicado: (2020)

Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series
por: Doi, Kent, et al.
Publicado: (2020)

Favipiravir for COVID-19 in a Patient on Hemodialysis
por: Hirai, Daisuke, et al.
Publicado: (2021)

Future of antivirals in COVID-19: The case of favipiravir
por: Kow, Chia Siang, et al.
Publicado: (2022)

The Anti-Influenza Virus Drug Favipiravir Has Little Effect on Replication of SARS-CoV-2 in Cultured Cells
por: Tomita, Yuriko, et al.
Publicado: (2021)

Effectiveness of favipiravir in COVID-19: a live systematic review
por: Özlüşen, Batu, et al.
Publicado: (2021)

Effectiveness of Early Favipiravir Therapy in Hospitalised COVID-19 Patients
por: Tawfik, Abdulrahman, et al.
Publicado: (2022)

Antiviral therapy for COVID-19: Derivation of optimal strategy based on past antiviral and favipiravir experiences
por: Shiraki, Kimiyasu, et al.
Publicado: (2022)

Favipiravir exposure and pregnancy outcome of COVID-19 patients
por: Tırmıkçıoğlu, Zeynep
Publicado: (2022)

PIONEER trial: favipiravir to treat moderate COVID-19
por: Shalhoub, Sarah
Publicado: (2023)

Solubility of favipiravir (as an anti-COVID-19) in supercritical carbon dioxide: An experimental analysis and thermodynamic modeling
por: Sajadian, Seyed Ali, et al.
Publicado: (2022)

Insights on the Quantitative Concurrent Fluorescence-Based Analysis of Anti-COVID-19 Drugs Remdesivir and Favipiravir
por: El-Awady, Mohamed, et al.
Publicado: (2022)

Favipiravir-induced Liver Injury in Patients with Coronavirus Disease 2019
por: Kumar, Pramod, et al.
Publicado: (2021)

Rational Defensive Medicine: Putting an End to the Nationwide Favipiravir Debate
por: Öncel, Selim
Publicado: (2022)

Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir
por: Guner, Rahmet, et al.
Publicado: (2021)

Favipiravir: A new and emerging antiviral option in COVID-19
por: Agrawal, Umang, et al.
Publicado: (2020)

Understanding the pharmacokinetics of Favipiravir: Implications for treatment of influenza and COVID-19
por: Ison, Michael G., et al.
Publicado: (2021)

A Favipiravir-induced Fever in a Patient with COVID-19
por: Kurita, Takashi, et al.
Publicado: (2020)

Regional trends in the use of steroids and favipiravir for COVID-19 treatment
por: Asai, Yusuke, et al.
Publicado: (2023)

An economical and practical procedure of favipiravir synthesis for the treatment of Covid-19
por: Karatas, Hacer, et al.
Publicado: (2022)

Favipiravir and hyperuricemia in patients with COVID-19—suggestions for future studies
por: Kow, Chia Siang, et al.
Publicado: (2023)

Reply to Cheng et al.: COVID-19 induces lower extent of cytokines, but damages vascular endothelium by IL-6 signaling
por: Kang, Sujin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jdcgtrl1itoeivf10neqog38a0